ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 188,49
-0,63%
Dow Jones
39 984,23
0,19%
DAX
18 738,81
-0,72%
Brent Oil
82,87
0,26%
Bitcoin
65 286,89
-1,47%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) Actualités

ARGX argenx SE

375,165
-1,80 (-0,48%)
Dernière mise à jour : 18:31:03
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
argenx SE ARGX NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-1,80 -0,48% 375,165 18:31:03
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
375,90 373,62 378,05 376,96
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
09/5/202413:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/5/202407:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
08/5/202412:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/5/202423:30GLOBEargenx announces results of Annual General Meeting of..
07/5/202407:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
02/5/202407:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
16/4/202407:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/3/202407:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/3/202421:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/3/202407:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
08/3/202412:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/3/202422:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29/2/202422:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/2/202407:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/2/202407:00GLOBEargenx to Present at Upcoming Investor Conferences
22/2/202407:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/2/202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/2/202407:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/1/202412:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/1/202407:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/1/202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202407:00GLOBEargenx Highlights 2024 Strategic Priorities
02/1/202407:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20/12/202318:37DJNArgenx Down Nearly 26%, on Pace for Record Percent Decrease..
20/12/202312:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202307:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28/11/202317:16DJNArgenx Down Over 10%, On Track for Largest Percent Decrease..
28/11/202313:03DJNArgenx Shares Down After Vyvgart Study Misses Primary..
28/11/202312:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202307:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
17/11/202312:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/11/202313:40GLOBEargenx Announces European Commission Approval of..
01/11/202321:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
31/10/202314:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202307:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202307:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
27/9/202322:42EDGAR2Form S-8 - Securities to be offered to employees in employee..
21/9/202314:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/9/202307:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/9/202307:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/8/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
27/7/202312:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/7/202307:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
24/7/202322:30GLOBEargenx announces closing of global offering
20/7/202322:51EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/7/202307:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
19/7/202323:58GLOBEargenx announces full exercise of underwriters’ option to..
19/7/202303:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
17/7/202322:58DJNArgenx Launches $750 Million Global Offering

Dernières Valeurs Consultées

NASDAQ
ARGX
argenx
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés